CG Oncology Inc. Common s...

AI Score

0

Unlock

27.91
-0.77 (-2.68%)
At close: Jan 14, 2025, 3:59 PM
28.60
2.47%
After-hours Jan 14, 2025, 07:43 PM EST
undefined%
Bid 27
Market Cap 2.12B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -15.87
PE Ratio (ttm) -1.76
Forward PE n/a
Analyst Buy
Ask 29.8
Volume 424,605
Avg. Volume (20D) 651,545
Open 28.92
Previous Close 28.68
Day's Range 27.70 - 28.92
52-Week Range 25.77 - 50.23
Beta undefined

About CGON

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 61
Stock Exchange NASDAQ
Ticker Symbol CGON

Analyst Forecast

According to 9 analyst ratings, the average rating for CGON stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 132.89% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 week ago · Source
+4.34%
CG Oncology shares are trading higher after TD Cow... Unlock content with Pro Subscription
1 month ago · Source
-6.54%
CG Oncology shares are trading lower. The company announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin.